Ultimately, Impower010 suggests that atezolizumab offers a safe and promising adjuvant treatment for patients with stage II–IIIA whose tumors express PD-L1 on 1% or more of tumors cells, especially for patients with PD-L1 expression on 50% or more tumor cells. Here, CD274 is linked to neoplasm.